Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 24, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Emerging Outsourcing Destinations: Pharmas Strategies and Growth Drivers
  Videos

Return

Emerging Outsourcing Destinations: Pharmas Strategies and Growth Drivers
JZMed

Jim Zhang, President, JZMed

Abstract
Emerging markets have been recognized as the key growth driver of the global pharmaceutical market.  They have thus received increasing attention from almost all drug companies around the world.  In addition to the attraction of the fast growing pharmaceutical market, the availability of a variety of outsourcing services at relatively low cost with increasing service capability and improved quality, is also attracting drug companies from all over the world to look for the outsourcing or collaboration opportunities in these countries, in particular China and India.  Currently, a large number of drug companies from all over the world are aggressively looking for partnerships with local companies or research organizations.  Meanwhile, to meet the high demand by the global drug companies and to position them well in these fast growing pharma outsourcing markets, almost all world major CROs and CMOs have made significant investments in these emerging countries.  This presentation will discuss in detail a series of new outsourcing strategies currently pursued by the global drug companies in these key emerging outsourcing countries and the strengths and weakness of the local service providers.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Adaptimmune Announces Interim Results from Pilot Trial of NY-ESO T Cells
Study reports encouraging response rate and safety profile.
Personalized Ovarian Cancer Vaccines
UConn Researchers have found a new way to identify protein mutations in cancer cells.
Study Finds Potential New Target to Treat Asthma Attacks Brought on by Colds
Results suggest that IL-25 could be a target for possible treatments to prevent asthma attacks.
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Leukemia Subtype Becomes More Common With Age
Genomic Analysis of 1,725 patients reveals the prevalence of Ph-like ALL increases with age.
Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes
UC San Diego is initial site for first-in-human testing of implanted cell therapy.
NIH to Launch Human Safety Study of Ebola Vaccine Candidate
Trial is First in Series of Accelerated Safety Studies of Ebola Vaccines.
NIH Announces the Launch of 3 Integrated Precision Medicine Trials
ALCHEMIST is for patients with certain types of early-stage lung cancer.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv